← Leaderboards
David A Dean
University Of South Alabama
$25,010,740
Attributed
$28,458,517
Total exposure
17
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$28,458,517 · 17
By mechanism
R01$24,812,144 · 13
R21$2,902,718 · 1
P01$727,655 · 1
R13$16,000 · 2
Top collaborators
- Arshad Rahman8 shared
- Bradley L. Nilsson4 shared
- Zhongren Zhou3 shared
Most similar at University Of South Alabama
Same institution · by research overlap
- Warren E Zimmer$1,169,301
- Jonathon Peter Audia$4,413,140
- Robert A Barrington$832,851
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyGene ExpressionGene DeliveryPlasmidsGene TransferAnimal ModelElectroporationProteinsLungCellsAnimalsMediatingIn VivoTranscription FactorGenesBaseCell NucleusCell TypeComplexIn VitroTransfectionAffectInjuryPlasmid Dna
Grant awards (72)
Intracellular Trafficking of DNA for Gene Therapy$398,090
R01 · FY2025 · GM · contact PI
Intracellular Trafficking of DNA for Gene Therapy$398,090
R01 · FY2024 · GM · contact PI
Mitigating Acute Lung Injury by Cell-specific Targeting of MTOR$589,429
R01 · FY2023 · HL
A multimodal delivery and treatment approach for Acute Lung Injury$582,391
R01 · FY2023 · HL · contact PI
Intracellular Trafficking of DNA for Gene Therapy$398,090
R01 · FY2023 · GM · contact PI
Mitigating Acute Lung Injury by Cell-specific Targeting of MTOR$589,429
R01 · FY2022 · HL
A multimodal delivery and treatment approach for Acute Lung Injury$582,391
R01 · FY2022 · HL · contact PI
Gene therapy for GERD-associated esophageal epithelial barrier dysfunction$550,568
R01 · FY2022 · DK · contact PI
Mitigating Acute Lung Injury by Cell-specific Targeting of MTOR$589,429
R01 · FY2021 · HL
A multimodal delivery and treatment approach for Acute Lung Injury$566,991
R01 · FY2021 · HL · contact PI
Gene therapy for GERD-associated esophageal epithelial barrier dysfunction$510,795
R01 · FY2021 · DK · contact PI
Mitigating Acute Lung Injury by Cell-specific Targeting of MTOR$589,429
R01 · FY2020 · HL
A multimodal delivery and treatment approach for Acute Lung Injury$566,991
R01 · FY2020 · HL · contact PI
Novel Peptide/siRNA Nanoparticles for Treatment of Acute Lung Injury$539,108
R01 · FY2020 · HL
Gene therapy for GERD-associated esophageal epithelial barrier dysfunction$530,161
R01 · FY2020 · DK · contact PI
Development of a gene therapy approach to treat acute lung injury using a preclinical, large animal model$697,556
R01 · FY2019 · HL · contact PI
Novel Peptide/siRNA Nanoparticles for Treatment of Acute Lung Injury$539,108
R01 · FY2019 · HL
Development of a gene therapy approach to treat acute lung injury using a preclinical, large animal model$759,156
R01 · FY2018 · HL · contact PI
Novel Peptide/siRNA Nanoparticles for Treatment of Acute Lung Injury$539,108
R01 · FY2018 · HL
Development of a gene therapy approach to treat acute lung injury using a preclinical, large animal model$776,235
R01 · FY2017 · HL · contact PI
Novel Peptide/siRNA Nanoparticles for Treatment of Acute Lung Injury$592,411
R01 · FY2017 · HL
Cell-specific gene delivery methods for expression and silencing in the lung$383,750
R01 · FY2017 · HL · contact PI
Cytoplasmic trafficking of non-viral gene therapy vectors$345,375
R01 · FY2017 · EB · contact PI
Development of a gene therapy approach to treat acute lung injury using a preclinical, large animal model$786,325
R01 · FY2016 · HL · contact PI
Cell-specific gene delivery methods for expression and silencing in the lung$383,750
R01 · FY2016 · HL · contact PI
Cytoplasmic trafficking of non-viral gene therapy vectors$345,375
R01 · FY2016 · EB · contact PI
Targeting Airway Smooth Muscle for Asthma Gene Therapy$380,456
R01 · FY2015 · HL · contact PI
Cell-specific gene delivery methods for expression and silencing in the lung$377,993
R01 · FY2015 · HL · contact PI
Cytoplasmic trafficking of non-viral gene therapy vectors$338,467
R01 · FY2015 · EB · contact PI
Cell-specific gene delivery methods for expression and silencing in the lung$383,750
R01 · FY2014 · HL · contact PI
Targeting Airway Smooth Muscle for Asthma Gene Therapy$378,525
R01 · FY2014 · HL · contact PI
Cytoplasmic trafficking of non-viral gene therapy vectors$345,375
R01 · FY2014 · EB · contact PI
2014 Bioelectrochemistry Gordon Research Conference & Gordon Research Seminar$3,000
R13 · FY2014 · CA · contact PI
DNA Nuclear Import Sequences for Cell-Specific Gene and Drug Delivery$410,307
R01 · FY2013 · GM · contact PI
Targeting Airway Smooth Muscle for Asthma Gene Therapy$367,710
R01 · FY2013 · HL · contact PI
Electroporation-mediated Pulmonary Gene Transfer for Acute Lung Injury$690,959
R21 · FY2012 · HL · contact PI
DNA Nuclear Import Sequences for Cell-Specific Gene and Drug Delivery$425,189
R01 · FY2012 · GM · contact PI
Targeting Airway Smooth Muscle for Asthma Gene Therapy$386,250
R01 · FY2012 · HL · contact PI
Cytoplasmic trafficking of non-viral gene therapy vectors$330,795
R01 · FY2012 · EB · contact PI
2012 Bioelectrochemistry Gordon Research Conference & Gordon Research Seminar$13,000
R13 · FY2012 · EB · contact PI
Electroporation-mediated Pulmonary Gene Transfer for Acute Lung Injury$712,679
R21 · FY2011 · HL · contact PI
DNA Nuclear Import Sequences for Cell-Specific Gene and Drug Delivery$406,457
R01 · FY2011 · GM · contact PI
Cytoplasmic trafficking of non-viral gene therapy vectors$330,261
R01 · FY2011 · EB · contact PI
Electroporation-mediated Pulmonary Gene Transfer for Acute Lung Injury$729,987
R21 · FY2010 · HL · contact PI
DNA Nuclear Import Sequences for Cell-Specific Gene and Drug Delivery$416,848
R01 · FY2010 · GM · contact PI
Alveolar Epithelial Cell-Specific Gene Therapy Plasmids$373,835
R01 · FY2010 · HL · contact PI
Cytoplasmic trafficking of non-viral gene therapy vectors$341,179
R01 · FY2010 · EB · contact PI
Electroporation-mediated Pulmonary Gene Transfer for Acute Lung Injury$384,101
R21 · FY2009 · HL · contact PI
Alveolar Epithelial Cell-Specific Gene Therapy Plasmids$373,835
R01 · FY2009 · HL · contact PI
Cytoplasmic trafficking of non-viral gene therapy vectors$346,500
R01 · FY2009 · EB · contact PI
Electroporation-mediated Pulmonary Gene Transfer for Acute Lung Injury$384,992
R21 · FY2008 · HL · contact PI
Alveolar Epithelial Cell-Specific Gene Therapy Plasmids$373,835
R01 · FY2008 · HL · contact PI
Gene transfer to the alveolar epithelium: effects of stretch$331,514
P01 · FY2007 · HL · contact PI
Alveolar Epithelial Cell-Specific Gene Therapy Plasmids$294,450
R01 · FY2007 · HL · contact PI
Vascular smooth muscle specific gene therapy vectors$271,707
R01 · FY2007 · HL · contact PI
Alveolar Epithelial Cell-Specific Gene Therapy Plasmids$54,485
R01 · FY2007 · HL · contact PI
Vascular smooth muscle specific gene therapy vectors$1
R01 · FY2007 · HL · contact PI
Alveolar Epithelial Cell-Specific Gene Therapy Plasmids$357,575
R01 · FY2006 · HL · contact PI
Vascular smooth muscle specific gene therapy vectors$280,120
R01 · FY2006 · HL · contact PI
Gene transfer to the alveolar epithelium and stretch$200,997
P01 · FY2006 · HL · contact PI
Vascular smooth muscle specific gene therapy vectors$287,157
R01 · FY2005 · HL
Gene transfer to the alveolar epithelium and stretch$195,144
P01 · FY2005 · HL
Vascular smooth muscle specific gene therapy vectors$287,444
R01 · FY2004 · HL
Vascular smooth muscle specific gene therapy vectors$307,342
R01 · FY2003 · HL
NUCLEAR TARGETING VECTORS FOR CORNEAL GENE THERAPY$257,250
R01 · FY2003 · EY
NUCLEAR TARGETING VECTORS FOR CORNEAL GENE THERAPY$257,250
R01 · FY2002 · EY
NUCLEAR TARGETING VECTORS FOR CORNEAL GENE THERAPY$294,000
R01 · FY2001 · EY
VASCULAR SMOOTH MUSCLE SPECIFIC GENE THERAPY VECTORS$187,315
R01 · FY2001 · HL
NUCLEAR TARGETING VECTORS FOR CORNEAL GENE THERAPY$228,792
R01 · FY2000 · EY
VASCULAR SMOOTH MUSCLE SPECIFIC GENE THERAPY VECTORS$164,805
R01 · FY2000 · HL
NUCLEAR TARGETING VECTORS FOR CORNEAL GENE THERAPY$51,308
R01 · FY2000 · EY
VASCULAR SMOOTH MUSCLE SPECIFIC GENE THERAPY VECTORS$14,045
R01 · FY2000 · HL